Clinical trial
Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine…
NCT00483470 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00483470 |
|---|---|
| Title | Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis A |
| Intervention type | Biological |
| Interventions | Hepatitis A vaccine AVAXIM 80U, Hepatitis A vaccine (HAVRIX 720) |
| Enrollment | 720 |
| Start date | Jun 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jun 7, 2007 |
| Last update posted | Jan 22, 2014 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: